Novartis AG
COMBINATION OF A MCL-1 INHIBITOR AND A STANDARD OF CARE TREATMENT FOR HEMATOLOGIC CANCERS, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF

Abstract:

A combination comprising a Mcl-1 inhibitor and a second anticancer agent, wherein the second anticancer agent is selected from anthracyclines, cytarabine and hypomethylating agents, and compositions and uses thereof.